UoH start-up claims breakthrough COVID treatment through stem cells

Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics

A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics,a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday. The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients. “A significant decrease in a set of inflammatory cytokines involved in the COVID-19 “cytokine storm”; with significantly improved patient survival and time to recovery was observed following the treatment,” claimed, an official spokesman in a press release.